SB203580__p38 MAP kinase inhibitor BCX 4431
Product Name
SB203580
Description
p38 MAP kinase inhibitor
Purity
>98% (HPLC)
CAS No.
152121-47-6
Molecular Formula
C21H16FN3OS
Molecular Weight
377.4
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO (50 mg/ml)
Source
Synthetic
Appearance
White to off-white powder
SMILES
C1=C(C=CC(=C1)C2=C(NHC(=N2)C3=CC=C(C=C3)S(C)=O)C4=CC=NC=C4)F
InChI
InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
InChIKey
CDMGBJANTYXAIV-UHFFFAOYSA-N
Safety Phrases
Classification:
Acute toxicity, Oral (Category 4), H302
Serious eye damage (Category 1), H318
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
H318 Causes serious eye damage.
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously wit h water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
P330 Rinse mouth.
P501 Dispose of contents/ container to an approved waste disposal plant
Cite This Product
SB203580 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-474)
Alternative Names
4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
176155
Scientific Background
SB203580 is a a pyridinyl imidazole that inhibits p38 MAP kinase. SB 203580 has also been shown to inhibit heat shock protein 27 (HSP 27) phosphorylation and has been shown to induce the activation of Raf-1. It displays 100-500-fold selectivity over LCK, GSK-3β and PKBα. SB203580 is cell permeable.
References
1. Hall-Jackson C. A., Goedert M., Hedge P., & Cohen P. (1999) Oncogene. 18(12): 2047–2054.
2. Saklatvala, J., et al. (1996) J. Bio. Chem. 271(12): 6586–6589.
3. Cuenda A., et al. (1995) FEBS Letters. 364(2): 229–233.
p38 MAP kinase inhibitor
Acute toxicity, Oral (Category 4), H302
Serious eye damage (Category 1), H318
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
H318 Causes serious eye damage.
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously wit h water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
P330 Rinse mouth.
P501 Dispose of contents/ container to an approved waste disposal plant
2. Saklatvala, J., et al. (1996) J. Bio. Chem. 271(12): 6586–6589.
3. Cuenda A., et al. (1995) FEBS Letters. 364(2): 229–233.